CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
Voriconazole is a strong CYP3A4 inhibitor and can raise the plasma concentrations of drugs that CYP3A4 metabolises (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Its SmPC lists cisapride among drugs that depend heavily on CYP3A4 for their metabolism. High plasma concentrations of these drugs are associated with serious or potentially life-threatening reactions (voriconazole SmPC, EMA). The pair has not been studied, but higher cisapride concentrations can prolong the corrected QT interval (QTc) and, rarely, cause torsade de pointes (voriconazole SmPC, EMA). Voriconazole itself has been associated with QTc prolongation (voriconazole SmPC, EMA).
Symptoms
The danger of the combination is prolongation of the corrected QT interval (QTc) and rare cases of torsade de pointes (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. Rare cases of arrhythmias (including torsade de pointes), cardiac arrest and sudden death have been reported in people taking voriconazole. These were usually seriously ill patients with several risk factors, such as previous cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicines that may have contributed (voriconazole label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The voriconazole summaries of product characteristics (SmPCs) name cisapride among contraindicated drugs whose metabolism is highly dependent on CYP3A4, and the interaction table also marks the combination as contraindicated (voriconazole SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The US voriconazole label contraindicates drugs on the same basis, but cisapride is not on its list (voriconazole label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the voriconazole documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe voriconazole with it (voriconazole SmPC, EMA). No document states how long to wait after stopping voriconazole before starting cisapride. Monitor potassium, magnesium and calcium and correct them as needed before and during voriconazole treatment (voriconazole SmPC, EMA, and FDA label). Use voriconazole with caution in congenital or acquired QTc prolongation, cardiomyopathy (especially with heart failure), sinus bradycardia and symptomatic arrhythmias, and with other drugs known to prolong the QTc interval (voriconazole SmPC, EMA, and FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026